<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="76706">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106962</url>
  </required_header>
  <id_info>
    <org_study_id>001-Boiskin</org_study_id>
    <nct_id>NCT02106962</nct_id>
  </id_info>
  <brief_title>Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients</brief_title>
  <official_title>Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Institute of Renal Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imprimis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>California Institute of Renal Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate how the use of Tranexamic acid and Bacitracin applied to the
      bleeding site after the hemodialysis fistula needle is removed will affect skin wound
      healing.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clotting Time</measure>
    <time_frame>13 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding Time</measure>
    <time_frame>13 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Loss</measure>
    <time_frame>13 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Compression Time</measure>
    <time_frame>13 Minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Infection</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Native Arteriovenous Fistula</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Tranexamic Acid</intervention_name>
    <description>A fixed amount of tranexamic acid and bacitracin will be applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site per visit (8 visits total).</description>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Bacitracin</intervention_name>
    <description>A fixed amount of tranexamic acid and bacitracin will be applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site per visit (8 visits total).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dialysis patients with fistulas (native arterio-venous)

        Exclusion Criteria:

          -  Previous sensitivity to or adverse reaction to Tranexamic acid or Bacitracin.

          -  Active infection.

          -  Stenosis of fistula.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Boiskin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Institute of Renal Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina Lorenzo, BS</last_name>
    <phone>858-637-4600</phone>
    <email>clorenzo@cairr.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fresenius Medical Care - Kearny Mesa</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Buchard</last_name>
      <email>lbuchard@cairr.com</email>
    </contact>
    <investigator>
      <last_name>Mark Boiskin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Mende, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dylan Steer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Insitute of Renal Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Lorenzo, BS</last_name>
      <phone>858-637-4600</phone>
      <email>clorenzo@cairr.com</email>
    </contact>
    <investigator>
      <last_name>Mark Boiskin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Mende, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dylan Steer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fresenious Medical Care - Rancho</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Buchard</last_name>
      <email>lbuchard@cairr.com</email>
    </contact>
    <investigator>
      <last_name>Mark Boiskin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Mende, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dylan Steer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>California Institute of Renal Research</investigator_affiliation>
    <investigator_full_name>Mark Boiskin</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>fistula</keyword>
  <keyword>clotting</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>bacitracin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Bacitracin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
